Fibrocell captures FDA approval for personalized wrinkle treatment

Fibrocell Science ($FCSC) has won FDA approval to market a new competitor to Botox which uses a sample of a person's cells to create an individualized therapy to smooth out the wrinkles-often called smile lines-that gather above a person's mouth. The company plans to harvest small quantities of tissue from patients and then isolate fibroblasts that will be used to generate a personalized cell treatment that can smooth skin. The treatment will be sold as laViv.

"The concept of using a patient's own collagen-making cells is a revolutionary way to help treat nasolabial fold wrinkles and help restore a fresh appearance," said Dr. Robert A. Weiss, a clinical associate professor at Johns Hopkins School of Medicine and an investigator for the laViv clinical trials. "Since this is a biological process that works over time, laViv is able to provide gradual and natural-looking results."

To fulfill a post marketing requirement of the FDA's, the company will set up a registry of about 2,700 patients to further evaluate the dermal filler's safety. Investigators recruited more than 400 patients to participate in two late-stage studies. Fibrocell's shares were up about 7 percent this morning.

- here's the Fibrocell release

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.